23-minute watch
| Talk 4
of 5
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Frederick Locke
Moffitt Cancer Center, Tampa, FL, USA
Dr Matthew Lunning
University of Nebraska Medical Center, NE, USA
Dr Frederick Locke, Moffitt Cancer Center, Tampa, FL, USA, and Dr Matthew Lunning, University of Nebraska Medical Center, NE, USA, summarise the key efficacy and safety data from the ZUMA-7, TRANSFORM, ALYCANTE and PILOT CAR T clinical studies
